FDA Remains Neutral On COVID-19 Boosters Ahead Of VRBPAC Meeting

By Kelly Lienhard / September 15, 2021 at 4:59 PM
FDA is not convinced about the efficacy of an additional shot of Pfizer’s approved COVID-19 vaccine, Comirnaty, for the general population, despite calls from the White House and Pfizer to roll out boosters. The agency released briefing documents ahead of its Friday (Sept. 17) meeting during which FDA’s Vaccines and Related Biological Products Advisory Committee will discuss Pfizer’s supplemental biological license application for a booster dose of Comirnaty. Pfizer proposes giving the third shot six months after people have received...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.